Multicenter retrospective study of cetuximab plus platinum-based chemotherapy for recurrent or metastatic oral squamous cell carcinoma
Multicenter retrospective study of cetuximab plus platinum-based chemotherapy for recurrent or metastatic oral squamous cell carcinoma
复制标题
DOI：
10.1007/s00280-018-3531-x
复制
发表时间：
2018-03-01
影响因子：
3
通讯作者：
Tohnai, Iwai
中科院分区：
文献类型：
--
作者：
Yanamoto, Souichi;Umeda, Masahiro;Tohnai, Iwai
本研究的目的是评估西妥昔单抗联合铂类化疗治疗复发或转移性口腔鳞状细胞癌（OSCC）患者的有效性和安全性，我们对2012年12月至2015年6月期间接受一线西妥昔单抗联合铂类化疗的患者进行了多中心回顾性观察研究。65名患者每周接受西妥昔单抗治疗（第1周，400 mg/m（2）;随后的几周，250 mg/m（2））加顺铂最多6个3周周期（80或100 mg/m2），第1天）或卡铂（第1天静脉输注1小时，曲线下面积为5 mg/mL/min）和5-氟尿嘧啶（800或1000 mg/m2/天，第1-4天）。接受西妥昔单抗联合铂类化疗的病情稳定患者继续接受西妥昔单抗治疗，直至疾病进展或出现不可接受的毒性，以先发生者为准，中位随访时间为10.5（范围1.2-34.2）个月。最佳总缓解率和疾病控制率分别为46.2%和67.7%。中位总生存期和无进展生存率分别为12.1和7.8个月。最常见的3-4级不良事件是皮疹（9.2%），其次是白细胞减少症（6.2%）。我们的多中心回顾性研究是迄今为止同类研究中规模最大的一项，其结果表明，一线西妥昔单抗联合铂类化疗适用于复发或转移性口腔鳞癌的全身治疗，且耐受性良好。
The purpose of this study was to assess the efficacy and safety of cetuximab plus platinum-based chemotherapy for patients specifically diagnosed with recurrent or metastatic oral squamous cell carcinoma (OSCC).We conducted a multicenter retrospective observational study of patients who underwent first-line cetuximab plus platinum-based chemotherapy between December 2012 and June 2015. 65 patients received weekly cetuximab (week 1, 400 mg/m(2); subsequent weeks, 250 mg/m(2)) plus a maximum of six 3-weekly cycles of cisplatin (80 or 100 mg/m(2), day 1) or carboplatin (at an area under the curve of 5 mg/mL/min as a 1-h intravenous infusion on day 1) and 5-fluorouracil (800 or 1000 mg/m(2)/day, days 1-4). Patients with stable disease who received cetuximab plus platinum-based chemotherapy continued to receive cetuximab until disease progression or unacceptable toxicities, whichever occurred first.The median follow-up was 10.5 (range 1.2-34.2) months. The best overall response and the disease control rates were 46.2 and 67.7%, respectively. The median overall survival and progression-free survival rates were 12.1 and 7.8 months, respectively. The most common grades 3-4 adverse events were skin rash (9.2%) followed by leukopenia (6.2%). None of the adverse events were fatal.The results of our multicenter retrospective study, which was the largest of its kind to date, suggest that first-line cetuximab plus platinum-based chemotherapy is suitable and well-tolerated for the systemic therapy of recurrent or metastatic OSCC.